PETVIVO HOLDINGS, INC. ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 2022 BioConnect Conference January 10-13, 2022 (VIRTUAL CONFERENCE)
January 04 2022 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets is pleased to announce
it will be featured as a presenting company at the H.C. Wainwright
BioConnect Conference. The conference is being held virtually on
January 10-13, 2022.
John Lai, Chief Executive Officer, of PetVivo,
will provide an overview of the Company's business during the
presentation.
If you are an institutional investor, and would
like to listen to the Company’s presentation, please click on the
following link (www.hcwevents.com/bioconnect) to register for the
conference. Over 500 corporate presentations & panels are
available on-demand during January 10-13, 2022.
Event: H.C. Wainwright BioConnect Conference
(Virtual Conference)
Date: January 10-13, 2022
Presentation Time: January 10, 2022 at 12:00 PM
EST
Location: Virtual Conference
PetVivo Webcast:
https://journey.ct.events/view/cdc183e0-5175-4ff4-967b-9f29e7706cf1
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is scheduled for
expanded commercial sale in the fourth quarter of this year.
About H.C. Wainwright &
Co.
H.C. Wainwright is a full‐service investment
bank dedicated to providing corporate finance, strategic advisory
and related services to public and private companies across
multiple sectors and regions. H.C. Wainwright & Co. also
provides research and sales and trading services to institutional
investors. According to Sagient Research Systems, H.C. Wainwright’s
team is ranked as the #1 Placement Agent in terms of aggregate CMPO
(confidentially marketed public offering), RD (registered direct
offering) and PIPE (private investment in public equity) executed
cumulatively since 1998.
For more information visit H.C. Wainwright &
Co. on the web at www.hcwco.com
CONTACT:
John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Apr 2023 to Apr 2024